SCHEMBL735328

SCHEMBL735328

CC12CC3CC(C)(C1)CC(NC=O)(C3)C2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 3/20 0.59
GRIN3B O60391 3/20 0.59
GRIN1 Q05586 3/20 0.59
GRIN2A Q12879 3/20 0.59
GRIN2B Q13224 3/20 0.59
GRIN2C Q14957 3/20 0.59
GRIN3A Q8TCU5 3/20 0.59
EPHX2 P34913 9/20 0.50
HDAC1 Q13547 4/20 0.43
HDAC8 Q9BY41 4/20 0.43
HDAC6 Q9UBN7 4/20 0.43
HDAC3 O15379 3/20 0.43
SLC22A1 O15245 1/20 0.42
LMNA P02545 1/20 0.42
ESR1 P03372 1/20 0.42
ADRB3 P13945 1/20 0.42
ACHE P22303 1/20 0.42
OPRK1 P41145 1/20 0.42
MTOR P42345 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14856654 1.00 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Memantine SCHEMBL1377007 0.90 GRIN1 (0.61) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Pyridine SCHEMBL27727842 0.84 GRIN2D (0.44) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4385378 0.82 TSHR (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL23367161 0.78
SCHEMBL8061377 0.76 GRIN1 (0.71) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1072142 0.76 GRIN1 (0.71) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL292343 0.74 GRIN1 (1.00) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5270620 0.72 GRIN1 (0.65) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL11656535 0.72 GRIN1 (0.95) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119936252-A Memantine hydrochloride and detection method of related substances thereof 宁夏医科大学 2025-05-06 CN claimed
EP-2274276-B1 PROCESS FOR THE MANUFACTURE OF MEMANTINE AND INTERMEDIATE PRODUCT MERZ PHARMA GMBH & CO KGAA (DE) 2014-07-09 EP claimed
US-8436209-B2 Process for the manufacture of memantine and intermediate product MERZ PHARMA GMBH & CO. KGAA (DE) 2013-05-07 US claimed
EP-2373612-B1 METHOD FOR PRODUCING MEMANTINE MERZ PHARMA GMBH & CO KGAA (DE) 2013-04-17 EP claimed
CN-102942490-A Synthesis of memantine hydrochloride SHAANXI ARK PHARMACEUTICAL CO LTD 2013-02-27 CN claimed
EP-1989175-B1 METHOD FOR PRODUCING 1-FORMAMIDO-3,5-DIMETHYLADAMANTANE MERZ PHARMA GMBH & CO KGAA (DE) 2012-09-19 EP claimed
US-8138375-B2 Method for producing 1-formamido-3,5-dimethyladamantane MERZ PHARMA GMBH & CO. KGAA (DE) 2012-03-20 US claimed
EP-2389351-A1 A PROCESS FOR PREPARING MEMANTINE Merz Pharma GmbH & Co. KGaA (DE) 2011-11-30 EP claimed
US-20110288336-A1 METHOD FOR PRODUCING MEMANTINE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-11-24 US claimed
US-20110282100-A1 PROCESS FOR PREPARING MEMANTINE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-11-17 US claimed
WO-2010083996-A1 A PROCESS FOR PREPARING MEMANTINE MERZ PHARMA GMBH & CO. KGAA (DE) 2010-07-29 WO claimed
WO-2010069555-A1 METHOD FOR PRODUCING MEMANTINE MERZ PHARMA GMBH & CO. KGAA (DE) 2010-06-24 WO claimed
US-20090299097-A1 Method for Producing 1-Formamido-3,5-Dimethyladamantane MERZ PHARMA GMBH & CO. KGAA (DE) 2009-12-03 US claimed
US-20090299096-A1 Amidoadamantanes and Method for Producing the Same JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) 2009-12-03 US claimed
WO-2009115334-A2 PROCESS FOR THE MANUFACTURE OF MEMANTINE AND INTERMEDIATE PRODUCT MERZ PHARMA GMBH & CO. KGAA (DE) 2009-09-24 WO claimed
EP-2103597-A1 Process for the manufacture of memantine and intermediate product Merz Pharma GmbH & Co.KGaA (DE) 2009-09-23 EP claimed
EP-1989177-A1 AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME Justus-Liebig-Universität Giessen (DE) 2008-11-12 EP claimed
EP-1989175-A1 METHOD FOR PRODUCING 1-FORMAMIDO-3,5-DIMETHYLADAMANTANE Merz Pharma GmbH & Co.KGaA (DE) 2008-11-12 EP claimed
WO-2007101535-A1 AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) 2007-09-13 WO claimed
WO-2007101536-A1 METHOD FOR PRODUCING 1-FORMAMIDO-3,5-DIMETHYLADAMANTANE MERZ PHARMA GMBH & CO. KGAA (DE) 2007-09-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299096-A1 Amidoadamantanes and Method for Producing the Same ADORA3, TAAR5, ADORA1 GRIN2D 1051/4885GRIN3B 1517/4885GRIN1 1026/4885
US-20090299097-A1 Method for Producing 1-Formamido-3,5-Dimethyladamantane DIMT1, NAAA, MRM1 GRIN2D 1136/4885GRIN3B 1445/4885GRIN1 736/4885
US-20110282100-A1 PROCESS FOR PREPARING MEMANTINE PSEN2, SLC6A2, PNMT GRIN2D 59/4885GRIN3B 35/4885GRIN1 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.